CAJ | 학술논문

目的：探讨甘精胰岛素替换预混胰岛素方案的临床疗效及长期可行性。方法将43例入组患者的预混胰岛素替换为甘精胰岛素,并调整口服降糖药物(OAD)。分别于治疗的第2、4、8、16周对患者进行实验室检查,测量项目包括：血糖、血脂、体质量指数、糖化血红蛋白(HbA1 c)、医疗费用及观察试验结束后患者继续使用甘精胰岛素的依从性。调查患者的生活质量。结果治疗16周后,患者的空腹血糖、餐后血糖、HbA1 c 分别下降了1.35 mmol/L、1.91 mmol/L、0.71%,胰岛素剂量减少11.33 U/d,生活质量得到提高,OAD 种类明显增加,医疗费用上涨235.6元/月(均 P <0.05)。研究结束后的第12周随访显示,仅28.2%的患者继续选择甘精胰岛素治疗。结论甘精胰岛素替换预混胰岛素能有效降低血糖并减少低血糖事件发生风险,但医疗费用较高。
목적：탐토감정이도소체환예혼이도소방안적림상료효급장기가행성。방법장43례입조환자적예혼이도소체환위감정이도소,병조정구복강당약물(OAD)。분별우치료적제2、4、8、16주대환자진행실험실검사,측량항목포괄：혈당、혈지、체질량지수、당화혈홍단백(HbA1 c)、의료비용급관찰시험결속후환자계속사용감정이도소적의종성。조사환자적생활질량。결과치료16주후,환자적공복혈당、찬후혈당、HbA1 c 분별하강료1.35 mmol/L、1.91 mmol/L、0.71%,이도소제량감소11.33 U/d,생활질량득도제고,OAD 충류명현증가,의료비용상창235.6원/월(균 P <0.05)。연구결속후적제12주수방현시,부28.2%적환자계속선택감정이도소치료。결론감정이도소체환예혼이도소능유효강저혈당병감소저혈당사건발생풍험,단의료비용교고。
Objective To investigate the clinical efficacy and long-term viability of insulin glargine switched from premixed insulin in type 2 diabetic patients.Methods Forty-three subjects were screened from outpatients with premixed insulin switched to insulin glargine and oral antidiabetic drugs(OAD).Respectively after treatment at 2,4,8, 1 6 weeks,the patients implemented laboratory examinations,measures including blood glucose,lipids,body mass index, glycosylated hemoglobin(HbA1 c)and medical expenses.The compliance of insulin glargine was evaluated at the fourth and twelfth week after the end of the study.The patients were evaluated for life quality.Results After treatment of 1 6 weeks,the level of fasting blood glucose,postprandial blood glucose and HbA1 c decreased 1.35 mmol/L,1.91 mmol/L,0.71%,separately;insulin dosage reduced 1 1.33 U/d;The life quality of the patients improved;types of OAD increased significantly;medical expenses rose ￥ 235.6 yuan per month (all P < 0.05 )Only 28.2% of the patients continued to use insulin glargine at the 12-weeks'follow-up after the intervention.Conclusion The glucose control after insulin glargine switched from premixed insulin showed obvious effect on diabetes control and reduced hypoglycemic events,while medical expenses are higher.